Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thymopeptide is an immunomodulatory agent consisting of a mixture of peptides, such as thymosin, derived from the thymus glands of animals (e.g., calves) or produced synthetically. It is primarily used to address immune deficiencies by enhancing cellular immune function. The mechanism of action involves promoting the maturation, differentiation, and activation of T-lymphocytes, balancing T-cell subsets, and stimulating the production of cytokines like interferons and interleukins. This helps restore and regulate the immune system's ability to fight infections and diseases. In China, thymopeptide is approved and marketed in various formulations, including enteric-coated tablets and injections, for treating conditions such as chronic hepatitis B, autoimmune diseases, and as an adjunctive therapy for cancer patients undergoing chemotherapy to boost their immune response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thymopeptide.